Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
about
Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imagingRecent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRIConsensus report from the 7th International Forum for Liver Magnetic Resonance ImagingEffect of hepatocyte-specific gadolinium-based contrast agents on hepatic fat-fraction and R2(⁎).Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular CarcinomaLiver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm.CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging featuresMRI features of hepatocellular carcinoma related to biologic behaviorLiver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.Investigation and management of hepatic incidentalomas.Consensus report from the 6th International forum for liver MRI using gadoxetic acid.Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.Hepatobiliary agents and their role in LI-RADS.Gadoxetic acid: pearls and pitfalls.Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma.Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.LI-RADS(®) ancillary features on CT and MRI.Non-focal liver signal abnormalities on hepatobiliary phase of gadoxetate disodium-enhanced MR imaging: a review and differential diagnosis.Added value of smooth hypointense rim in the hepatobiliary phase of gadoxetic acid-enhanced MRI in identifying tumour capsule and diagnosing hepatocellular carcinoma.Improvement of gadoxetate arterial phase capture with a high spatio-temporal resolution multiphase three-dimensional SPGR-Dixon sequence.Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73.Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.MRI for hepatocellular carcinoma: a primer for magnetic resonance imaging interpretation.Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.
P2860
Q26822764-10C99012-86F8-47B2-802D-6D7E8F69D0BBQ28075361-408956CA-DE0B-41AA-A9A3-25304455E787Q28088807-36A33D7B-26BD-4FC9-BF27-372CDA1BBF72Q30303112-307C2838-68E0-4D7D-92DA-C1068CC778B3Q30448049-53E7008B-3188-4A49-ABF1-3BA363EDBA74Q31108230-E4965D02-5331-4E2E-8C6A-767CD31D17A1Q34682228-4BE1F3F0-D929-4747-AC55-17C062775B6AQ35619951-2EB471A5-6345-4319-9249-C0109E909FF3Q36333396-07EBFD33-6447-4F68-A399-787F6C220BF8Q38031005-14F66631-2963-4803-9F4C-3C61083CEBF9Q38219801-505F52C8-1C41-4AB0-8758-014D376EDA92Q38238010-B91B8D37-DFF3-4DFC-A94D-708964EC7894Q38257321-C15DFFE7-4F11-4B90-B9EB-9508FE2C64F2Q38329089-93201A1D-7B74-4C94-B345-8E8F80595663Q38434362-12FF1EF4-EF8B-4A38-A07C-7A9BFA263128Q38635644-98E513A1-BD83-483D-9718-4B81D2509E98Q38684422-C8DA5450-03B8-404D-A625-CB05D9CA7B1FQ38710312-DCC3E803-1FAD-421F-ABD7-2ABCA751FEA0Q38747328-AA0DF384-829B-4F24-8E01-B6D53F3A9525Q39259950-C75AA85C-3E84-4866-9687-DDE89A0E61F3Q46155546-90FCB7D1-2ACE-4DC2-AEA9-601F482906E5Q47158829-B0A459C4-D1B1-435E-B9ED-DAFFB9B154D6Q51816847-3ABAB58A-5082-4DFF-A0F6-35823CCD127AQ52969072-6B82E82E-3459-4C72-9995-7504938782CBQ52983889-FB5D1C9B-0377-4493-8DAF-33A1649EC045Q53109359-F62E6E4E-0E4F-4CB4-9BDD-50A6442217F0Q53123794-F154A801-EFF1-4974-B89F-DCEFF6167B0BQ54501471-29F97C59-927D-424A-B61E-5564D1406022
P2860
Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Differentiation of hepatic hyp ...... anced hepatobiliary phase MRI.
@en
Differentiation of hepatic hyp ...... anced hepatobiliary phase MRI.
@nl
type
label
Differentiation of hepatic hyp ...... anced hepatobiliary phase MRI.
@en
Differentiation of hepatic hyp ...... anced hepatobiliary phase MRI.
@nl
prefLabel
Differentiation of hepatic hyp ...... anced hepatobiliary phase MRI.
@en
Differentiation of hepatic hyp ...... anced hepatobiliary phase MRI.
@nl
P2093
P356
P1476
Differentiation of hepatic hyp ...... hanced hepatobiliary phase MRI
@en
P2093
Ki Whang Kim
Mi-Suk Park
Myeong-Jin Kim
Young Nyun Park
P304
P356
10.2214/AJR.10.5845
P407
P577
2011-07-01T00:00:00Z